What happened
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
SourceHanif Medisiana PublisherpublicationBiotech
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Publication signal: Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceHanif Medisiana PublisherLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceHanif Medisiana PublisherLinked output
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation TriallpaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Safety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall
Genomics and Gene Editing
Controlled AISci Stage A topic for Genomics and Gene Editing.
Timeline
- publicationSafety and Efficacy of Subretinal AAV-CRISPR/Cas9 Gene Editing for Rhodopsin-Mutant Retinitis Pigmentosa: A Phase I/IIa Dose-Escalation Triall